29 results
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
19 Jan 24
Regulation FD Disclosure
2:33pm
to strengthen overall communications, transparency, and engagement. For more information, visit https://www.watertowerresearch.com/home.
Investor Contact:
Colin
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
24 Jul 23
Regulation FD Disclosure
4:26pm
of investors while helping to strengthen overall communications, transparency, and engagement. For more information, visit https://www.watertowerresearch.com
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
19 May 23
Regulation FD Disclosure
1:41pm
” opens the door to reach a much broader and diverse set of investors while helping to strengthen overall communications, transparency, and engagement
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
4:01pm
-sized companies, including cross-border operations, makes Marcum well suited to support our efforts to deliver the high level of financial transparency
8-K
EX-99.1
xdzgc mc7mbgt
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
3:47pm
424B5
qitu7nnqu1t c7d
3 Jun 22
Prospectus supplement for primary offering
9:45pm
424B3
rtlzoy uyw9sjq66
25 Apr 22
Prospectus supplement
5:02pm
424B3
jyhv wuhq
7 Apr 22
Prospectus supplement
4:46pm
S-3
y3iuzu46iwlp
4 Feb 22
Shelf registration
4:36pm
8-K/A
EX-99.1
h2hr9 xqbb
22 Dec 21
Audited Financial Statements
12:00am
8-K/A
EX-99.2
ek82uorxyvohh
22 Dec 21
Audited Financial Statements
12:00am
10-K
cs84tu3rc09
24 Sep 21
Annual report
7:31am
424B3
e1nd6y 024zf
22 Jul 21
Prospectus supplement
10:27am
424B3
og3roxqtdt25u5o7mh9
16 Mar 21
Prospectus supplement
12:00am